TMR Post-Market Study Should Evaluate Long-Term Efficacy - FDA Panel
This article was originally published in The Gray Sheet
Postmarket surveillance of PLC Medical's Heart Laser transmyocardial revascularization (TMR) device should address the long-term reproducibility of its safety and efficacy and further assess mortality associated with the system, FDA's Circulatory System Devices Panel recommended April 24 at its meeting in Gaithersburg, Maryland.
You may also be interested in...
Edwards LifeSciences' agreement to become the exclusive distributor of PLC Medical Systems' next-generation transmyocardial revascularization system, announced Jan. 9, demonstrates the Baxter spin-off's belief in the validity of a technology that has yet to be fully embraced by the market.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.